Vancouver-based psychedelic medicine company Albert Labs began trading its common shares on the Canadian Securities Exchange (CSE) under the ticker symbol “ABRT” on March 10, 2022.
The listing comes in conjunction with the completion of the previously announced reverse take-over (RTO) of ME. Resource Corp. (MEC). The company also closed a debt settlement and private placement offering of 18.9 million common shares at a rate of CAD 0.25 (USD 0.20) per share, raising gross proceeds of CAD 4.7 million (USD 3.7 million).
The proceeds from the placement and the company’s existing cash balance will be used to manufacture and distribute its natural psilocybin-based prescription drug KRN-101 for clinical trials and carry out real-world evidence (RWE) trials together with partners.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.